Additionally, tirzepatide—a dual GIP/GLP-1 receptor agonist—demonstrated substantial efficacy in patients with metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis. This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatohepatitis.